FDA approves GSK RSV vaccine for adults 50 to 59

A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022.Hannah Mckay | ReutersThe Food and Drug Administration on Friday expanded the approval of GSK's respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the potentially lethal virus. The...

Read more...

Moderna, Merck cancer vaccine with Keytruda improved survival in trial

Moderna and Merck released more positive three-year data Monday on their experimental vaccine, given to patients with the most deadly form of skin cancer in combination with the therapy Keytruda.The vaccine together with Merck's Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a...

Read more...

Pfizer lung cancer drug shows promising long-term trial results

CHICAGO — Pfizer on Friday said its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial, which may help establish it as the new standard treatment for the condition.The company's medicine helped patients live longer without seeing their cancer progress, and most...

Read more...

FDA approves Moderna RSV vaccine for seniors

Nikos Pekiaridis | Lightrocket | Getty ImagesThe Food and Drug Administration on Friday approved Moderna's vaccine for respiratory syncytial virus for adults ages 60 and above, the company's second-ever product to enter the U.S. market. The decision is a win for Moderna, which desperately needs another revenue source amid plunging...

Read more...

Roche weight loss drug shows promising results in early trial

A logo at the Roche Holding AG headquarters in Basel, Switzerland, on Thursday, Feb. 1, 2024.Bloomberg | Getty ImagesRoche on Thursday said its experimental weight loss drug showed promising results in an early-stage trial, boosting the company's bid to compete in the booming market for those treatments.The Swiss company joined...

Read more...